These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 15860185)

  • 1. [Congestive heart failure in Spain: cost-effectiveness and cost-benefit analyses of treatment with beta-blockers].
    Díez Manglano J
    Rev Clin Esp; 2005 Apr; 205(4):149-56. PubMed ID: 15860185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In heart failure, all beta-blockers are not necessarily equal.
    Tang WH; Militello M; Francis GS
    Cleve Clin J Med; 2003 Dec; 70(12):1081-7. PubMed ID: 14686687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Economic analysis of the treatment of heart failure with beta-blockers].
    Díez-Manglano J
    Med Clin (Barc); 2013 Sep; 141(6):265-70. PubMed ID: 23597957
    [No Abstract]   [Full Text] [Related]  

  • 4. Cost-effectiveness of beta-blocker therapy with metoprolol or with carvedilol for treatment of heart failure in Canada.
    Levy AR; Briggs AH; Demers C; O'Brien BJ
    Am Heart J; 2001 Sep; 142(3):537-43. PubMed ID: 11526370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial.
    Jabbour A; Macdonald PS; Keogh AM; Kotlyar E; Mellemkjaer S; Coleman CF; Elsik M; Krum H; Hayward CS
    J Am Coll Cardiol; 2010 Apr; 55(17):1780-7. PubMed ID: 20413026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Older adults with heart failure treated with carvedilol, bisoprolol, or metoprolol tartrate: risk of mortality.
    Perreault S; de Denus S; White M; White-Guay B; Bouvier M; Dorais M; Dubé MP; Rouleau JL; Tardif JC; Jenna S; Haibe-Kains B; Leduc R; Deblois D
    Pharmacoepidemiol Drug Saf; 2017 Jan; 26(1):81-90. PubMed ID: 27859924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic impact of beta blockade in heart failure.
    Gregory D; Udelson JE; Konstam MA
    Am J Med; 2001 May; 110 Suppl 7A():74S-80S. PubMed ID: 11334781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness of carvedilol for heart failure.
    Delea TE; Vera-Llonch M; Richner RE; Fowler MB; Oster G
    Am J Cardiol; 1999 Mar; 83(6):890-6. PubMed ID: 10190405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cost-effectiveness analysis of bisoprolol for heart failure.
    Varney S
    Eur J Heart Fail; 2001 Jun; 3(3):365-71. PubMed ID: 11378009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Benefits of Carvedilol, Bisoprolol, and Metoprolol Controlled Release/Extended Release in Hemodialysis Patients with Heart Failure: A 10-Year Cohort.
    Tang CH; Wang CC; Chen TH; Hong CY; Sue YM
    J Am Heart Assoc; 2016 Jan; 5(1):. PubMed ID: 26738790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bisoprolol compared with carvedilol and metoprolol succinate in the treatment of patients with chronic heart failure.
    Fröhlich H; Torres L; Täger T; Schellberg D; Corletto A; Kazmi S; Goode K; Grundtvig M; Hole T; Katus HA; Cleland JGF; Atar D; Clark AL; Agewall S; Frankenstein L
    Clin Res Cardiol; 2017 Sep; 106(9):711-721. PubMed ID: 28434020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness results from the US Carvedilol Heart Failure Trials Program.
    Vera-Llonch M; Menzin J; Richner RE; Oster G
    Ann Pharmacother; 2001; 35(7-8):846-51. PubMed ID: 11485131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carvedilol, Bisoprolol, and Metoprolol Use in Patients With Coexistent Heart Failure and Chronic Obstructive Pulmonary Disease.
    Su VY; Chang YS; Hu YW; Hung MH; Ou SM; Lee FY; Chou KT; Yang KY; Perng DW; Chen TJ; Liu CJ
    Medicine (Baltimore); 2016 Feb; 95(5):e2427. PubMed ID: 26844454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do pharmacological differences among beta-blockers affect their clinical efficacy in heart failure?
    Di Lenarda A; Sabbadini G; Sinagra G
    Cardiovasc Drugs Ther; 2004 Mar; 18(2):91-3. PubMed ID: 15293370
    [No Abstract]   [Full Text] [Related]  

  • 15. The evaluation of β-adrenoceptor blocking agents in patients with COPD and congestive heart failure: a nationwide study.
    Liao KM; Lin TY; Huang YB; Kuo CC; Chen CY
    Int J Chron Obstruct Pulmon Dis; 2017; 12():2573-2581. PubMed ID: 28894360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating the effectiveness of different beta-adrenoceptor blockers in heart failure patients.
    Lin TY; Chen CY; Huang YB
    Int J Cardiol; 2017 Mar; 230():378-383. PubMed ID: 28041715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [For the first time beta blockers are in direct comparison With carvedilol weak hearts beat longer].
    MMW Fortschr Med; 2003 Jul; 145(27-28):60. PubMed ID: 14587195
    [No Abstract]   [Full Text] [Related]  

  • 18. Reimbursement claims analysis of outcomes with carvedilol and metoprolol.
    Luzier AB; Antell LA; Chang LL; Xuan J; Roth DA
    Ann Pharmacother; 2002 Mar; 36(3):386-91. PubMed ID: 11895048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carvedilol reduces the costs of medical care in severe heart failure: an economic analysis of the COPERNICUS study applied to the United Kingdom.
    Stewart S; McMurray JJ; Hebborn A; Coats AJ; Packer M;
    Int J Cardiol; 2005 Apr; 100(1):143-9. PubMed ID: 15820297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beta-blockers in heart failure. The 'new wave' of clinical trials.
    Krum H
    Drugs; 1999 Aug; 58(2):203-10. PubMed ID: 10473016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.